The PRIS programme aims to catalyse, boost and transfer the best ideas of the professionals of the Health Sector in the region.
TITTAN Thematic Area2: Inside-Out Innovation, looks for bridging the gap between research results and the market, promoting the matching of researchers and investors/buyers
In this sense, PRIS is an innovation programme, that transfers research results to the market. What is more remarkable is that it is open to the entire health system (researchers, nurses, etc.), to all technologies (drugs, diagnostics, devices, etc.) in all readiness levels (proof of concept, prototype, etc). The first edition was in 2013 and the second call for proposals was launched in 2015.
The daily role of ACIS in PRIS is identify, manage and add value to projects in close cooperation with the three Galician Biomedical Foundations (Fundación IDIS, Fundación Biomédica Galicia Sur and Fundación Profesor Novoa Santos) and with the professionals of the Galician Health Public System.
PRIS is a useful tool for adding value to research projects by identifying good ideas and teams, reducing risks and consulting the market from the very beginning. The phases of the PRIS programme are:
P1: Identification of R&D projects, which are being developed in Galician hospitals with results with market potential by competent teams.
P2: Pre-validation with the market and external consultants the strengths and weaknesses of the projects.
P3: Development of strategic plans for the most interesting projects.
P4: Financial Support of co-development plans for the selected projects, in collaboration with companies.
PRIS needed 5 professionals:
3 (1 for each Galician Biomedical Foundations) working with researchers
1 in administrative tasks
1 coordinates of the programme
First Edition was granted by Public Administration:
1.4 M € for research at hospitals (managed by Foundations).
1 M € for companies.
Evidence of success
2 start-ups launched:
• Platform - Microbiology diagnosis
• Platform - Vaccines
• Hemodynamics - Hemofilter Simulator
• Oncology - Diagnosis Colorectal cancer
• Neurology - Therapy against the ICTUS (in the course to be transferred to a pharma company)
• Nephrology - Genetic Diagnosis (in negotiation to start offering services)
2 technologies already incorporated:
• Emotional Training - Psychiatry
• HemotoolSoftware - Angiography
-Lack of investors specialized in the biomedical sector.
-Local private companies are reluctant to invest in R&D results.
-Limited connections with international partners to help with the translation to the market.
-Many projects lack of enough resources to demonstrate industrial interest.
Potential for learning or transfer
This good practice can inspire public authorities in need of catalysing and boosting the investigation of their researchers/professionals in the Health Sector to be transferred to the market. It fosters innovation, reducing the gap between research and the market.
The programme identifies health research projects that are being developed and with commercial potential. It selects the most interesting ones and supports them by collaborating in the development of a Valorization and Commercialization Plan for each project. Finally, it finances the co-development of these plans, in collaboration with companies, through the public procurement of innovation process. In this way, companies, specially SMEs, know the most challenging and promising research projects in Health, joining their teams in an early stage of development (with demonstrated positive preliminary results). To achieve this collaboration, the programme organise meetings with local and international investors.
Please login to see the expert opinion of this good practice.